EU drug watchdog reviews Celltrion's COVID-19 antibody treatment
Europe's drug regulator said on Wednesday it had started a real-time review of South Korean drugmaker Celltrion's experimental COVID-19 antibody-based treatment, regdanvimab.
The European Medicines Agency said its human medicines committee was assessing the first set of data it received from animal studies and human clinical trials, and will continue to study them as more data was submitted. (https://bit.ly/3dHpXlr)
ALSO READ
-
Middle Corridor Could Create 2 Million Jobs and Transform Trade in Nine Nations
-
Historic Move: U.S. Army Base in Poland Signals Stronger Alliance
-
Europe on the Brink: Slovak PM Advocates for Peace Amid Rising Tensions
-
Diplomatic Exclusion Raises Alarm in U.S. Military Review
-
Europe's Migration Crisis: Fewer Arrivals, More Fatalities
Google News